Heron Therapeutics Files 2025 Annual Report
Ticker: HRTX · Form: ARS · Filed: Apr 30, 2026 · CIK: 0000818033
| Field | Detail |
|---|---|
| Company | Heron Therapeutics, Inc. /De/ (HRTX) |
| Form Type | ARS |
| Filed Date | Apr 30, 2026 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: annual-report, pharmaceuticals, sec-filing
TL;DR
Heron Therapeutics filed its 2025 ARS on 4/30/26. Check financials.
AI Summary
Heron Therapeutics, Inc. filed its Annual Report to Security Holders (ARS) on April 30, 2026, for the period ending December 31, 2025. The company, headquartered in San Diego, CA, is involved in the Pharmaceutical Preparations industry.
Why It Matters
This filing provides shareholders with a comprehensive overview of Heron Therapeutics' financial performance and operational activities for the fiscal year 2025.
Risk Assessment
Risk Level: low — This is a routine annual filing providing historical financial information.
Key Numbers
- 669263 — ARS Document Size (Size of the primary ARS filing document.)
- 923325 — Submission Text File Size (Size of the complete submission text file.)
Key Players & Entities
- HERON THERAPEUTICS, INC. (company) — Filer
- 0000818033 (company) — CIK Number
- SAN DIEGO CA 92121 (location) — Mailing and Business Address
- 2025-12-31 (date) — Period of Report
- 2026-04-30 (date) — Filing Date
FAQ
What is the CIK number for Heron Therapeutics, Inc.?
The CIK number for Heron Therapeutics, Inc. is 0000818033.
When was the ARS filing accepted by the SEC?
The ARS filing was accepted on 2026-04-30 at 14:10:19.
What is the fiscal year end for Heron Therapeutics?
The fiscal year end for Heron Therapeutics is December 31 (1231).
What is the SIC code for Heron Therapeutics?
The SIC code for Heron Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
What is the primary document type filed?
The primary document type filed is an ARS (Annual Report to Security Holders).
Filing Details
This Form ARS (Form ARS) was filed with the SEC on April 30, 2026 regarding HERON THERAPEUTICS, INC. /DE/ (HRTX).